

Alicante, 24th April 2024

COMMUNICATION – MARKET NOTICE - FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.5.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter “FacePhi” or “the Company”) hereby notifies the following:

The Company published, in 21st July of 2023, the resolutions adopted by the Extraordinary General Shareholders’ Meeting held on that date, which included, as the first point, the delegation to the Board of Directors of the power to issue notes convertible into shares of the Company in favour of Nice & Green, S.A. (“Nice & Green”), with the exclusion of pre-emptive subscription rights, for a maximum conversion amount of €20,000,000, as well as to increase de share capital by the amount necessary to cover the conversion of said notes.

This agreement was amended and duly published on 19th January 2024, in the following terms:

- Reducing the maximum amount that the investor can invest, from the initial amount of 20 million euros to 11.1 million euros. The amount pending investment at the date of signing the addendum was 4.2 million euros (420 bonds).
- From that said amount, Facephi would issue up to 7 tranches of 60 convertible bonds (600,000 euros) at one-month intervals. All other circumstances and agreements between the parties remain unchanged.

Last 22nd of April, the Board of Directors adopted a resolution, under the aforementioned delegation of powers, to issue a fourth issuance of 60 convertible bonds for a total nominal amount of 600,000 euros (“Convertible Bonds 4th Tranche 24”), and Nice & Green is the sole beneficiary of this issuance.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró
Chairman of the Board of Directors